Maplight Therapeutics (NASDAQ:MPLT) Cut to Strong Sell at Wall Street Zen

Posted by Brenda Bartman on Oct 6th, 2026

Wall Street Zen downgraded shares of Maplight Therapeutics (NASDAQ:MPLT – Free Report) from a sell rating to a strong sell rating in a research report released on Saturday,Wall Street Zen reports.

Several other equities analysts have also recently issued reports on the company. Craig Hallum restated a “buy” rating and set a $25.00 price objective on shares of Maplight Therapeutics in a research note on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Maplight Therapeutics in a report on Monday, July 27th. Needham & Company LLC dropped their price objective on shares of Maplight Therapeutics from $45.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. HC Wainwright decreased their target price on Maplight Therapeutics from $45.00 to $26.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Finally, BMO Capital Markets assumed coverage on shares of Maplight Therapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $46.00 price target for the company. Four equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.50.

View Our Latest Research Report on MPLT

Maplight Therapeutics Stock Performance

MPLT opened at $9.27 on Friday. The company has a 50-day moving average of $12.06 and a 200-day moving average of $22.99. The company has a market capitalization of $515.23 million and a P/E ratio of -0.22. Maplight Therapeutics has a 1-year low of $9.10 and a 1-year high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.40) by $0.08. As a group, sell-side analysts expect that Maplight Therapeutics will post -5.12 earnings per share for the current fiscal year.

Insider Transactions at Maplight Therapeutics

In related news, Director Troy Cox bought 15,620 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was purchased at an average price of $9.52 per share, for a total transaction of $148,702.40. Following the transaction, the director directly owned 15,620 shares of the company’s stock, valued at approximately $148,702.40. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James Lillie sold 22,082 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $12.54, for a total transaction of $276,908.28. Following the transaction, the insider directly owned 202,380 shares in the company, valued at approximately $2,537,845.20. The trade was a 9.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Maplight Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MPLT. Legal & General Group Plc acquired a new stake in Maplight Therapeutics in the second quarter worth approximately $37,000. The Manufacturers Life Insurance Company acquired a new position in shares of Maplight Therapeutics during the 2nd quarter valued at $252,000. Deutsche Bank AG bought a new stake in shares of Maplight Therapeutics in the 2nd quarter worth $370,000. ADAR1 Capital Management LLC acquired a new stake in shares of Maplight Therapeutics in the second quarter valued at $950,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Maplight Therapeutics in the second quarter valued at $1,090,000.

About Maplight Therapeutics

(Get Free Report)

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric and neurological disorders. The company focuses on conditions for which existing treatments may provide limited benefits or cause significant side effects.

MapLight uses a neuroscience-focused drug discovery and development approach to identify therapies intended to address the underlying biology of central nervous system disorders. Its pipeline includes investigational small-molecule treatments being studied for conditions such as schizophrenia and other serious mental health disorders.

The company conducts research and clinical development in the United States.